Latest news with #Tucson
Yahoo
2 days ago
- Business
- Yahoo
Umbrella Labs Expands Research Portfolio with Availability of Retatrutide (LY3437943), a Next-Generation Triple Agonist Peptide
TUCSON, AZ / / June 2, 2025 / Umbrella Labs, a leading supplier of advanced research chemicals, announced the expansion of its peptide catalog to include Retatrutide (LY3437943), an investigational triple agonist peptide developed for use in scientific and academic research. This addition marks a significant milestone in the company's commitment to supporting cutting-edge research in metabolic disease, obesity, and type 2 diabetes mellitus (T2DM). Retatrutide has gained attention within the scientific community due to its unique ability to activate three key receptors involved in metabolic regulation: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This multi-receptor mechanism offers a promising new direction for researchers investigating novel treatments for obesity-related diseases. "We are proud to offer Retatrutide as part of our mission to provide academic and institutional researchers with the most innovative compounds available," said Samuel Yanner, Director of Scientific Operations at Umbrella Labs. "The peptide's clinical and preclinical data demonstrate its potential as a transformative research molecule." Scientific Highlights: Preclinical and Clinical Validation In comparative rodent studies, Retatrutide outperformed GLP-1 monotherapy and the dual agonist Tirzepatide, producing over 30% weight reduction while improving liver lipid profiles, insulin sensitivity, and inflammatory markers (Ma et al., 2025). A Phase 2 human trial led by Jastreboff et al. (2023) demonstrated up to 24.2% weight loss in non-diabetic obese participants, along with significant improvements in blood pressure, fasting glucose, LDL cholesterol, and HbA1c. These outcomes exceed the performance benchmarks of currently approved GLP-1-based therapeutics, including semaglutide. Expanding Research Horizons: Metabolic, Hepatic, and Cardiovascular Implications Retatrutide's diverse effects have fueled interest in multiple areas of academic investigation: Obesity and Weight Management: The triple receptor action mimics metabolic responses seen in bariatric surgery, with non-invasive delivery. T2DM Research: Demonstrated reductions in HbA1c (up to 2.2%) and possible β-cell preservation. NAFLD/NASH Models: Reduction in hepatic fat, ALT/AST normalization, and improved lipid oxidation suggest promising utility. Cardiovascular Metrics: Lower CRP and triglycerides, with HDL elevation, signal potential long-term cardiac benefit. Emerging exploratory areas include microdosing studies in appetite regulation, mitochondrial function, and speculative neuroendocrine roles due to GLP-1 expression in the central nervous system. Commitment to Quality: Umbrella Labs as a Trusted Supplier Retatrutide remains an investigational compound not approved for human use and is offered strictly for in vitro and animal-based research by qualified institutions. Umbrella Labs ensures cGMP-compliant manufacturing, third-party analytical testing, and reliable batch documentation for all peptides. Researchers interested in sourcing Retatrutide can find the compound listed at:Buy Retatrutide (LY3437943) - Umbrella Labs For additional research peptides and SARMs, visit the Umbrella Labs homepage. About Umbrella Labs Umbrella Labs is a premier supplier of research-grade peptides, SARMs, and other investigational compounds used by universities, pharmaceutical developers, and independent research teams. With a focus on purity, testing transparency, and customer support, Umbrella Labs continues to lead the field in supplying next-generation biochemicals for science-driven innovation. Media Contact Samuel YannerDirector of Scientific OperationsUmbrella Labs1-866-289-7276support@ E Hemisphere Loop, Tucson, AZ 85706 References Coskun T, Sloop KW, Loghin C, et al. LY3437943, a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Improves Metabolic Parameters in Preclinical Models of Obesity. Cell Metab. 2018;28(5):710-722.e10. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Triple-hormone-receptor agonist Retatrutide in adults with obesity: a randomized, double-blind, phase 2 trial. N Engl J Med. 2023;389(13):1134-1145. Ma X, Zhang L, Su Y, et al. Comparative efficacy of GLP-1/GIP/glucagon receptor agonism in diabetic mice: insights into Retatrutide's hepatometabolic benefits. J Endocrinol Invest. 2025;48(1):55-66. Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277-289. Killion EA, Wang J, Yie J, et al. Glucagon receptor activation increases energy expenditure and modulates lipoprotein metabolism in mice. Proc Natl Acad Sci USA. 2018;115(5):E1051-E1060. SOURCE: Umbrella Labs View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- General
- Yahoo
Space photo of the day for May 30, 2025
When you buy through links on our articles, Future and its syndication partners may earn a commission. A bright meteor, also called a fireball, is seen falling into Earth's atmosphere. From the perspective of the camera, it appears in the sky above the dome of Kitt Peak National Observatory. Kitt Peak National Observatory is in the Sonoran Desert, in Tucson, Arizona. The area was chosen for its access to dark skies and its altitude — over a mile (2.1 kilometers) above sea level — placing the telescope above most of our planet's thick atmosphere. According to NOIRLab (National Optical-Infrared Astronomy Research Laboratory), which, like, Kitt Peak is a project of the National Science Foundation, a meteor streak has to be brighter than how the planets appear in the sky (an apparent magnitude of –4 or brighter) to be considered a "fireball." You can read more about meteors and learn when meteor showers are expected this year. You can also read more about Kitt Peak National Observatory.
The Sun
5 days ago
- Automotive
- The Sun
Hyundai considering 1% price hike on US vehicles to counter tariff hit, Bloomberg News reports
HYUNDAI Motor is considering a 1% price increase on its entire U.S. lineup, looking to soften a hit from U.S. President Donald Trump's tariffs, Bloomberg News reported on Thursday, citing people familiar with the matter. The price hikes could come as soon as next week and would affect the suggested retail price of every model in its lineup, the report said, adding that they would apply to newly built vehicles, leaving cars that are already in dealer lots unaffected. The South Korean automaker is also likely to raise charges on shipping and fees for options such as floor mats and roof rails in a move that would help it avoid further raising the base price of its vehicles, Bloomberg News said. Reuters could not immediately confirm the report. In a statement, a Hyundai spokesperson said that no final decisions have been made on pricing changes following the June 2 conclusion of the automaker's current program. 'We will continue to adapt to shifts in supply and demand, and regulations, with a flexible pricing strategy and targeted incentive programs and always find ways to add value to our customers,' the spokesperson said. The industry has been dealing with higher supply chain costs due to Trump's tariffs, while concerns of a recession have led consumers to tighten their budgets. Hyundai has already taken steps to mitigate impacts from the automotive levies, including moving some Tucson crossovers production from Mexico to the United States and launching a task force aimed at cushioning some of the hit.
The Sun
5 days ago
- Automotive
- The Sun
Hyundai may raise US car prices amid tariff pressures
HYUNDAI Motor is considering a 1% price increase on its entire U.S. lineup, looking to soften a hit from U.S. President Donald Trump's tariffs, Bloomberg News reported on Thursday, citing people familiar with the matter. The price hikes could come as soon as next week and would affect the suggested retail price of every model in its lineup, the report said, adding that they would apply to newly built vehicles, leaving cars that are already in dealer lots unaffected. The South Korean automaker is also likely to raise charges on shipping and fees for options such as floor mats and roof rails in a move that would help it avoid further raising the base price of its vehicles, Bloomberg News said. Reuters could not immediately confirm the report. In a statement, a Hyundai spokesperson said that no final decisions have been made on pricing changes following the June 2 conclusion of the automaker's current program. 'We will continue to adapt to shifts in supply and demand, and regulations, with a flexible pricing strategy and targeted incentive programs and always find ways to add value to our customers,' the spokesperson said. The industry has been dealing with higher supply chain costs due to Trump's tariffs, while concerns of a recession have led consumers to tighten their budgets. Hyundai has already taken steps to mitigate impacts from the automotive levies, including moving some Tucson crossovers production from Mexico to the United States and launching a task force aimed at cushioning some of the hit.
CNA
5 days ago
- Automotive
- CNA
Hyundai considering 1% price hike on US vehicles to counter tariff hit, Bloomberg News reports
Hyundai Motor is considering a 1 per cent price increase on its entire U.S. lineup, looking to soften a hit from U.S. President Donald Trump's tariffs, Bloomberg News reported on Thursday, citing people familiar with the matter. The price hikes could come as soon as next week and would affect the suggested retail price of every model in its lineup, the report said, adding that they would apply to newly built vehicles, leaving cars that are already in dealer lots unaffected. The South Korean automaker is also likely to raise charges on shipping and fees for options such as floor mats and roof rails in a move that would help it avoid further raising the base price of its vehicles, Bloomberg News said. The industry has been dealing with higher supply chain costs due to Trump's tariffs, while concerns of a recession have led consumers to tighten their budgets. Hyundai has already taken steps to mitigate impacts from the automotive levies, including moving some Tucson crossovers production from Mexico to the United States and launching a task force aimed at cushioning some of the hit.
